Product Description: Durlobactam sodium salt (ETX2514) is a broad-spectrum β-lactamase inhibitor with IC50s of 4, 14 and 190 nM for Class A KPC-2, Class C AmpC and Class D OXA-24, respectively. For the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii[1].
Applications: COVID-19-immunoregulation
Formula: C8H10N3NaO6S
References: [1]Durand-Réville TF, et al. ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including <i>Acinetobacter baumannii</i>. Nat Microbiol. 2017 Jun 30;2:17104./[2]González-Bello C. Recently developed synthetic compounds with anti-infective activity. Curr Opin Pharmacol. 2019 Oct;48:17-23./[3]Barnes MD, et al. Targeting Multidrug-Resistant Acinetobacter spp.: Sulbactam and the Diazabicyclooctenone β-Lactamase Inhibitor ETX2514 as a Novel Therapeutic Agent. mBio. 2019 Mar 12;10(2):e00159-19.
CAS Number: 1467157-21-6
Molecular Weight: 299.24
Compound Purity: 99.62
Research Area: Infection
Solubility: H2O : ≥ 100 mg/mL
Target: Bacterial
Deutsch
English
